Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials

By sjmartinez • September 7, 2023

André F, Su F, Solovieff N, Hortobagyi G, Chia S, Neven P, Bardia A, D Tripathy, Lu YS, Lteif A, Taran T, Babbar N, Slamon D, Arteaga CL. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann Oncol. 2023 Sep 4:S0923-7534(23)00826-8. doi: 10.1016/j.annonc.2023.08.011. Epub ahead of print. PMID: 37673211.

Tags: Advanced breast cancer, biomarkers, CDK4/6 inhibitor, Hematology/Oncology, overall survival, Publications, ribociclib

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer

Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol[...]

Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology

Antonarelli G, Pérez-García JM, Gion M, Rugo H, Schmid P, Bardia A, Hurvitz S, Harbeck N, Tolaney SM, Curigliano G, Llombart-Cussac A, Cortés J. Redefining[...]

Microcytosis Merits Evaluation: A Case Report of Hemoglobin S With Hereditary Persistence of Fetal Hemoglobin (HbS-HPFH Syndrome)

Daniel CE, Bejjani A. Microcytosis Merits Evaluation: A Case Report of Hemoglobin S With Hereditary Persistence of Fetal Hemoglobin (HbS-HPFH Syndrome). Cureus. 2025 Feb 10;17(2):e78827.[...]